Cite
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy
MLA
A. Christopoulou, et al. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e8a5aa7649250ca8a5967556c4307652&authtype=sso&custid=ns315887.
APA
A. Christopoulou, Claudia Proto, Marina Chiara Garassino, Diego Signorelli, Giulio Metro, Panagiota Economopoulou, Andrea Camerini, Giuseppe Lo Russo, Helena Linardou, Panagiotis Baxevanos, Alfredo Addeo, Domenico Galetta, Marco Banini, Beatriz Jimenez, Giannis Mountzios, Pamela Pizzutilo, Alessandro De Toma, Alex Friedlaender, Paris Kosmidis, … Giuseppe Luigi Banna. (2021). Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Chicago
A. Christopoulou, Claudia Proto, Marina Chiara Garassino, Diego Signorelli, Giulio Metro, Panagiota Economopoulou, Andrea Camerini, et al. 2021. “Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e8a5aa7649250ca8a5967556c4307652&authtype=sso&custid=ns315887.